BLUFFDALE, Utah, July 11, 2024 — Med 7, LLC (www.med7cbd.com) announces the granting of a US patent for Hempzorb81™ for proving clinical benefits. This patent highlights Hempzorb81™ as a novel full-spectrum hemp CBD compound proven to increase intestinal absorption resulting in higher potency and a more rapid onset of action. Med 7 uses micelle technology to increase this absorption and bioavailability.
“Absorption and onset of action have been the Achilles Heel for cannabis related products, “said Matt Smith CEO of Med 7. “CBD and the other cannabinoids have a documented oral bioavailability of 6% and an onset of action between 60-90 minutes. Our micellized cannabinoids have a proven oral bioavailability of 85% and an onset of action of 15 minutes.”
“We believe that the granting of this additional US patent for Med 7 is a testament to the Company’s dedication to advancing health and well-being by offering cutting-edge, safe, non-pharmaceutical options for conditions that have a dramatic effect on the quality of life.” said Smith. “Med 7 is one of the few Hemp based CBD companies doing the clinical research so that consumers of these products know how and where they can be safely used.”
About Med 7
Med 7® is a technology-driven company that markets and distributes health and wellness products to medical professionals. Hempzorb81™ is a full spectrum hemp product made with Purzorb® technology, which mimics the body’s natural process of absorption by converting oil-based nutrients into water-soluble products. Hempzorb81™ is patent pending for other human health conditions.
For more information: Contact Med7, LLC: 801-577-4223, public.relations@med7usa.com, www.med7cbd.com
To view the complete patent: 12011470 (uspto.gov)


